COEP
insider transactionsCoeptis Therapeutics Holdings, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Brian Cogley KEY
Chief Financial Officer
$0
12.5K sh
Own +125%
-
Exercise·M
Brian Cogley KEY
Chief Financial Officer
$105.6K
10.0K sh · $10.56
Own +80%
-
Grant·A
Director
$0
3.2K sh
Own +57%
-
Exercise·M
Director
$60.2K
5.7K sh · $10.56
Own +175%
-
Grant·A
David Mehalick KEY
CEO and President
$0
51.2K sh
Own +18%
-
Exercise·M
David Mehalick KEY
CEO and President
$1.0M
148.9K sh · $7.05
Own +82%
-
Grant·A
VP Operations
$0
20.0K sh
Own +40%
-
Exercise·M
VP Operations
$104.1K
10.0K sh · $10.41
Own +17%
-
Grant·A
Director
$0
3.2K sh
Own +57%
-
Exercise·M
Director
$60.2K
5.7K sh · $10.56
Own +175%
-
Grant·A
Director
$0
3.2K sh
Own +33%
-
Exercise·M
Director
$60.2K
5.7K sh · $10.56
Own +76%
-
Grant·A
VP Compliance and Secy
$0
12.5K sh
Own +24%
-
Exercise·M
VP Compliance and Secy
$10.6K
1.0K sh · $10.56
Own +2%
-
Grant·A
Director
$0
3.2K sh
Own +57%
-
Exercise·M
Director
$60.2K
5.7K sh · $10.56
Own +175%
-
Grant·A
Director
$0
3.2K sh
Own +1%
-
Exercise·M
Director
$60.2K
5.7K sh · $10.56
Own +2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 11, 2026 | Brian Cogley KEY | Grant A | 12.5K | $0 |
| Feb 11, 2026 | Brian Cogley KEY | Exercise M | 10.0K | $105.6K |
| Feb 11, 2026 | Philippe Deschamps | Grant A | 3.2K | $0 |
| Feb 11, 2026 | Philippe Deschamps | Exercise M | 5.7K | $60.2K |
| Feb 11, 2026 | David Mehalick KEY | Grant A | 51.2K | $0 |
| Feb 11, 2026 | David Mehalick KEY | Exercise M | 148.9K | $1.0M |
| Feb 11, 2026 | Daniel Alexander Yerace | Grant A | 20.0K | $0 |
| Feb 11, 2026 | Daniel Alexander Yerace | Exercise M | 10.0K | $104.1K |
| Feb 11, 2026 | Tara Desilva | Grant A | 3.2K | $0 |
| Feb 11, 2026 | Tara Desilva | Exercise M | 5.7K | $60.2K |
| Feb 11, 2026 | Gene Salkind | Grant A | 3.2K | $0 |
| Feb 11, 2026 | Gene Salkind | Exercise M | 5.7K | $60.2K |
| Feb 11, 2026 | Christine Elise Sheehy | Grant A | 12.5K | $0 |
| Feb 11, 2026 | Christine Elise Sheehy | Exercise M | 1.0K | $10.6K |
| Feb 11, 2026 | Christopher P. Cochran | Grant A | 3.2K | $0 |
| Feb 11, 2026 | Christopher P. Cochran | Exercise M | 5.7K | $60.2K |
| Feb 11, 2026 | Chris Calise | Grant A | 3.2K | $0 |
| Feb 11, 2026 | Chris Calise | Exercise M | 5.7K | $60.2K |
About COEP insider trading
This page tracks insider transactions for Coeptis Therapeutics Holdings, Inc. (COEP) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.